Market Cap 575.59M
Revenue (ttm) 414.29M
Net Income (ttm) -99.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -24.09%
Debt to Equity Ratio 0.67
Volume 4,585,600
Avg Vol 1,421,620
Day's Range N/A - N/A
Shares Out 81.99M
Stochastic %K 80%
Beta 2.10
Analysts Sell
Price Target $6.54

Company Profile

Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists,...

Industry: Health Information Services
Sector: Healthcare
Phone: 206 926 8100
Address:
1201 Third Avenue, Suite 1700, Seattle, United States
CoenMcCall
CoenMcCall May. 16 at 5:47 PM
$ACCD USAU - Low float, high potential sleeper waking up 🚨⏳ 📍 CK Gold Project - Fully permitted. $459M NPV. 36% IRR. Not drill-and-pray, this is build-and-bank. 💰 $7.3M Raised via warrants - No public offering, no dilution. Let that sink in. 📊 No debt - Cleanest balance sheet you’ll find in this space. 🥇 Gold + 🥉Copper exposure - Dual upside in two strong commodities. 📈 +60% in last 12 weeks, chart coiling at 52W highs. Tight float = potential face-melter. 🔋 Volume slowly building - You can chase later or position now. 👀 Watching for breakout confirmation. If this goes, it really goes. 🟢 Accumulating 🟢 High reward setup 🟢 $15+ not out of the question While the herd apes into exhausted runners, I’m here quietly loading USAU with actual fundamentals and an actual plan. DYOR. But don’t say you weren’t warned🚀💰🔥
0 · Reply
phillysea12
phillysea12 Apr. 8 at 2:06 PM
$ACCD piece of shit stock. 😡
0 · Reply
G101SPM
G101SPM Apr. 8 at 1:30 PM
$ACCD $7.02 bid. *DAC (7) $4.62. EXIT $12.00. BRIEF: Accolade: Transcarent announced the successful completion of its merger with Accolade. note: The transaction, valued at approximately $621 million, has received all necessary regulatory and shareholder approvals and Accolade is now part of a privately held company, and its common stock will no longer be listed on Nasdaq. * Click SEARCH (magnifying glass) icon on our landing page to review the postings.
1 · Reply
Mergerbrief
Mergerbrief Apr. 7 at 12:15 PM
$ACCD / Transcarent - Possible Close
0 · Reply
G101SPM
G101SPM Apr. 4 at 2:19 PM
$ACCD $7.02 bid. * DAC (dollar average cost includes 7 transactions to reduce cost to $4.62). Last at $3.60 (6.28.24). CHANGE EXIT TO $12.00 FROM $8.50. UPDATE: The merger is tentatively scheduled to close prior to the market open on April 8, 2025, subject to regulatory approval. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on April 7, 2025. If the merger closes as anticipated, the stock will remain halted on the day of closing (April 8th) and will be suspended effective April 9, 2025. * Click SEARCH (magnifying glass) icon on our landing page to review the postings.
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 30 at 4:29 AM
$ACCD Digging ACCD's personalized healthcare play. Innovative data-driven approach targeting complex healthcare navigation. Watching how they scale and expand their member base. Potential long-term healthcare tech winner. great article: https://beyondspx.com/article/accolade-accd-delivering-personalized-healthcare-solutions-at-scale
0 · Reply
Mergerbrief
Mergerbrief Mar. 27 at 12:23 PM
$ACCD / Transcarent - $ACCD Shareholder Vote
0 · Reply
EZ_Money11
EZ_Money11 Feb. 28 at 12:20 PM
$ACCD Maybe wait to see if it fills the gap around $3.70…..
0 · Reply
ribockski
ribockski Feb. 24 at 3:37 AM
1. Accolade Inc. ($ACCD): A healthcare company, Accolade has experienced a significant 97% increase in its stock price over the past 30 days, indicating strong growth potential. 2. Akero Therapeutics Inc. ($AKRO): A biopharmaceutical company focused on developing treatments for non-alcoholic steatohepatitis (NASH), Akero has seen its stock price rise by 96.2% over the past month. 3. OppFi Inc. ($OPFI): A financial technology company, OppFi has demonstrated a 93.1% increase in its stock price over the past 30 days, suggesting robust growth prospects.
0 · Reply
Quantum_Capital_LLC
Quantum_Capital_LLC Feb. 23 at 10:57 AM
$MPLN $APPS $CRNC $TUYA what I am currently buying/accumulating; they have strong momentum & technical indicators are favorable for either near term bullish move or long term positive move. $ACCD on watch.
0 · Reply
Latest News on ACCD
Pernod completes sale of wine portfolio to Accolade Wines owner

Apr 30, 2025, 2:45 AM EDT - 2 months ago

Pernod completes sale of wine portfolio to Accolade Wines owner


Transcarent Completes Merger With Accolade

Apr 8, 2025, 9:22 AM EDT - 2 months ago

Transcarent Completes Merger With Accolade


Accolade Welcomes Oshi Health to Trusted Partner Ecosystem

Mar 6, 2025, 9:00 AM EST - 4 months ago

Accolade Welcomes Oshi Health to Trusted Partner Ecosystem


Why Is Accolade Stock Trading Over 100% On Tuesday?

Jan 8, 2025, 1:33 PM EST - 6 months ago

Why Is Accolade Stock Trading Over 100% On Tuesday?


Transcarent To Acquire Accolade

Jan 8, 2025, 8:30 AM EST - 6 months ago

Transcarent To Acquire Accolade


Accolade to Announce Fiscal Third Quarter 2025 Financial Results

Dec 16, 2024, 8:00 AM EST - 6 months ago

Accolade to Announce Fiscal Third Quarter 2025 Financial Results


Accolade: A GARP Stock Trading Well Under 1X Revenues

Dec 5, 2024, 5:05 AM EST - 7 months ago

Accolade: A GARP Stock Trading Well Under 1X Revenues


Accolade To Present at Upcoming Investor Conferences

Nov 13, 2024, 8:00 AM EST - 8 months ago

Accolade To Present at Upcoming Investor Conferences


Accolade Welcomes Renalogic to Trusted Partner Ecosystem

Oct 15, 2024, 9:00 AM EDT - 9 months ago

Accolade Welcomes Renalogic to Trusted Partner Ecosystem


Accolade, Inc. (ACCD) Q2 2025 Earnings Call Transcript

Oct 8, 2024, 10:27 AM EDT - 9 months ago

Accolade, Inc. (ACCD) Q2 2025 Earnings Call Transcript


Accolade Announces Results for Fiscal Second Quarter 2025

Oct 8, 2024, 7:00 AM EDT - 9 months ago

Accolade Announces Results for Fiscal Second Quarter 2025


Accolade to Announce Fiscal Second Quarter 2025 Financial Results

Sep 18, 2024, 8:00 AM EDT - 10 months ago

Accolade to Announce Fiscal Second Quarter 2025 Financial Results


CoenMcCall
CoenMcCall May. 16 at 5:47 PM
$ACCD USAU - Low float, high potential sleeper waking up 🚨⏳ 📍 CK Gold Project - Fully permitted. $459M NPV. 36% IRR. Not drill-and-pray, this is build-and-bank. 💰 $7.3M Raised via warrants - No public offering, no dilution. Let that sink in. 📊 No debt - Cleanest balance sheet you’ll find in this space. 🥇 Gold + 🥉Copper exposure - Dual upside in two strong commodities. 📈 +60% in last 12 weeks, chart coiling at 52W highs. Tight float = potential face-melter. 🔋 Volume slowly building - You can chase later or position now. 👀 Watching for breakout confirmation. If this goes, it really goes. 🟢 Accumulating 🟢 High reward setup 🟢 $15+ not out of the question While the herd apes into exhausted runners, I’m here quietly loading USAU with actual fundamentals and an actual plan. DYOR. But don’t say you weren’t warned🚀💰🔥
0 · Reply
phillysea12
phillysea12 Apr. 8 at 2:06 PM
$ACCD piece of shit stock. 😡
0 · Reply
G101SPM
G101SPM Apr. 8 at 1:30 PM
$ACCD $7.02 bid. *DAC (7) $4.62. EXIT $12.00. BRIEF: Accolade: Transcarent announced the successful completion of its merger with Accolade. note: The transaction, valued at approximately $621 million, has received all necessary regulatory and shareholder approvals and Accolade is now part of a privately held company, and its common stock will no longer be listed on Nasdaq. * Click SEARCH (magnifying glass) icon on our landing page to review the postings.
1 · Reply
Mergerbrief
Mergerbrief Apr. 7 at 12:15 PM
$ACCD / Transcarent - Possible Close
0 · Reply
G101SPM
G101SPM Apr. 4 at 2:19 PM
$ACCD $7.02 bid. * DAC (dollar average cost includes 7 transactions to reduce cost to $4.62). Last at $3.60 (6.28.24). CHANGE EXIT TO $12.00 FROM $8.50. UPDATE: The merger is tentatively scheduled to close prior to the market open on April 8, 2025, subject to regulatory approval. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on April 7, 2025. If the merger closes as anticipated, the stock will remain halted on the day of closing (April 8th) and will be suspended effective April 9, 2025. * Click SEARCH (magnifying glass) icon on our landing page to review the postings.
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 30 at 4:29 AM
$ACCD Digging ACCD's personalized healthcare play. Innovative data-driven approach targeting complex healthcare navigation. Watching how they scale and expand their member base. Potential long-term healthcare tech winner. great article: https://beyondspx.com/article/accolade-accd-delivering-personalized-healthcare-solutions-at-scale
0 · Reply
Mergerbrief
Mergerbrief Mar. 27 at 12:23 PM
$ACCD / Transcarent - $ACCD Shareholder Vote
0 · Reply
EZ_Money11
EZ_Money11 Feb. 28 at 12:20 PM
$ACCD Maybe wait to see if it fills the gap around $3.70…..
0 · Reply
ribockski
ribockski Feb. 24 at 3:37 AM
1. Accolade Inc. ($ACCD): A healthcare company, Accolade has experienced a significant 97% increase in its stock price over the past 30 days, indicating strong growth potential. 2. Akero Therapeutics Inc. ($AKRO): A biopharmaceutical company focused on developing treatments for non-alcoholic steatohepatitis (NASH), Akero has seen its stock price rise by 96.2% over the past month. 3. OppFi Inc. ($OPFI): A financial technology company, OppFi has demonstrated a 93.1% increase in its stock price over the past 30 days, suggesting robust growth prospects.
0 · Reply
Quantum_Capital_LLC
Quantum_Capital_LLC Feb. 23 at 10:57 AM
$MPLN $APPS $CRNC $TUYA what I am currently buying/accumulating; they have strong momentum & technical indicators are favorable for either near term bullish move or long term positive move. $ACCD on watch.
0 · Reply
ajmrtxl
ajmrtxl Feb. 18 at 4:15 PM
$ACCD latest data from Squeezefinder
0 · Reply
jasonthegreat1
jasonthegreat1 Jan. 21 at 5:58 PM
$ACCD $5 puts exp March 21st are virtually free. Good hedge just in case things don't work out. Call it insurance.
0 · Reply
djotc
djotc Jan. 10 at 9:07 PM
$ACCD this thing should have nose dived by
1 · Reply
d_risk
d_risk Jan. 10 at 4:01 PM
$ACCD - Accolade Inc. Common Stock - 10Q - Updated Risk Factors New risks from the pending Transcarent merger include business disruptions, employee uncertainty, legal challenges, deal restrictions, and significant fallout if it fails. Completion remains uncertain. #Risk https://d-risk.ai/ACCD/10-Q/2025-01-10
0 · Reply
kuhii
kuhii Jan. 10 at 2:39 PM
$ACCD did they even report
0 · Reply
NextBigRun
NextBigRun Jan. 10 at 1:43 AM
Top watch for a crazy move ticker -🚨 MCVT 🚨 Check it out, no dilution. Tiny float, cash flow positive. And now a massive short squeeze setting up. $SANA $ACCD $CURR $SILO
0 · Reply
topstockalerts
topstockalerts Jan. 9 at 7:52 PM
$ACCD can she keep going up?
0 · Reply
anachartanalyst
anachartanalyst Jan. 9 at 7:01 PM
$ACCD https://anachart.com/wp-content/uploads/ana_temp/1736449293_soc-img.jpg
0 · Reply